title: Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.
abstract: OBJECTIVE
  A randomized controlled trial was conducted to find out whether antiviral therapy in patients with hepatitis B-related hepatocellular carcinoma (HCC) improves long-term survival after hepatic resection.
  
  
  BACKGROUND
  Despite advances in surgery and in multidisciplinary treatment, there is still no effective adjuvant treatment to prevent HCC recurrence after R0 resection for HCC. Whether antiviral therapy is useful in reducing postoperative HCC recurrence is unclear.
  
  
  METHODS
  Between May 2007 and April 2008, patients who received R0 hepatic resection for HBV-related HCC were randomly assigned to receive no treatment (the control group, n = 100) or antiviral therapy (adefovir 10 mg/d, the antiviral group, n = 100).
  
  
  RESULTS
  The baseline clinical, laboratory, and tumor characteristics of the 2 groups were comparable. The 1-, 3-, and 5-year recurrence-free survival rates for the antiviral group and the control group were 85.0%, 50.3%, 46.1% and 84.0%, 37.9%, 27.1%, respectively. The corresponding overall survival rates for the 2 groups were 96.0%, 77.6%, 63.1% and 94.0%, 67.4%, 41.5%, respectively. The recurrence-free survival and overall survival for the antiviral group were significantly better than the control group (P = 0.026, P = 0.001). After adjusting for the confounding prognostic factors in a Cox model, the relative risks of recurrence and death for antiviral treatment were 0.651 [95% confidence interval (CI): 0.451-0.938; P = 0.021] and 0.420 (95% CI: 0.271-0.651; P < 0.001). Antiviral therapy was an independent protective factor of late tumor recurrence (HR = 0.348, 95% CI: 0.177-0.687; P = 0.002) but not of early tumor recurrence [hazard ratio (HR) = 0.949, 95% CI: 0.617-1.459; P = 0.810].
  
  
  CONCLUSIONS
  In patients with hepatitis B-related HCC, adefovir antiviral therapy reduced late HCC recurrence and significantly improved overall survival after R0 hepatic resection.
authors: *Eastern Hepatobiliary Surgery Hospital, National Innovation Alliance for Hepatitis & Liver Cancer, Shanghai, China; and †Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, People's Republic of China.
authors: Gang
authors: G
authors: Huang
authors: Wan Yee
authors: WY
authors: Lau
authors: Zhen-Guang
authors: ZG
authors: Wang
authors: Ze-Ya
authors: ZY
authors: Pan
authors: Sheng-Xian
authors: SX
authors: Yuan
authors: Feng
authors: F
authors: Shen
authors: Wei-Ping
authors: WP
authors: Zhou
authors: Meng-Chao
authors: MC
authors: Wu
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000601:surgery* / Q000821:virology*; D004279:DNA, Viral / Q000097:blood; D006509:Hepatitis B / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D017093:Liver Failure / Q000209:etiology; D008113:Liver Neoplasms / Q000401:mortality / Q000601:surgery* / Q000821:virology*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D063065:Organophosphonates / Q000627:therapeutic use*; D011446:Prospective Studies; D016019:Survival Analysis; D014775:Virus Activation; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D063065:Organophosphonates; C053001:adefovir; D000225:Adenine